🧫 Experiment Protocol
Exploratorybreast cancerYAP1, CAPZA1MCF-7 and MDA-MB-231 human breast cancer cell linesproposed
This experiment investigated the mechanism by which silibinin induces cell cycle arrest in breast cancer cells. The study examined both hormone-sensitive MCF-7 and triple-negative MDA-MB-231 breast cancer cells to determine how silibinin treatment affects cell cycle progression. The researchers found that silibinin induces G2/M phase arrest in both cell lines through inhibition of the YAP pathway. Additionally, they discovered that silibinin significantly reduces F-actin assembly, which is positively regulated by YAP through transcriptional control of polymerization factors. The study demonstrated that F-actin disassembly is not merely a consequence of YAP inhibition but actively contributes to cell cycle arrest. Using molecular techniques including siRNA transfection and cytoskeletal disruption with Cytochalasin D, they showed that F-actin assembly disturbance directly contributes to cell cycle arrest independent of YAP activity.
PRIMARY OUTCOME
G2/M cell cycle arrest and F-actin disassembly
EXPECTED OUTCOMES
Silibinin treatment expected to induce cell cycle arrest through YAP inhibition; discovered that F-actin disassembly is a critical mediator of this effect
SUCCESS CRITERIA
Demonstration of G2/M arrest, reduced F-actin assembly, and restoration of cell cycle progression upon F-actin stabilization
PROTOCOL
Cell culture, silibinin treatment, cell cycle analysis, F-actin staining and microscopy, siRNA transfection (si-YAP/TAZ, si-Capza1), Cytochalasin D treatment, qRT-PCR, protein analysis